Patents

We are actively seeking opportunities for in-licensing of complementary technologies and out-licensing of Sengenics biomarker patents. Please contact us to arrange a discussion.

KREX™, IMMUNOME™,  SYMPHONI™ and OncoREX™ are registered trademarks of Sengenics and is protected by one or more of the following Patents:

NoPatent NumberDescriptionsView Patent
1JP4377242 Methods of determining method, and a folded state to increase the protein tag, and solubility including biotinylation domainView Patent
2AU2002352355 Protein arrays for allelic variants and uses thereofView Patent
3CA2469403 Protein arrays for allelic variants and uses thereofView Patent
4EP1456668Protein arrays for allelic variants and uses thereofView Patent
5AU2003238441 Protein tag comprising a biotinylation domain and method for increasing solubility and determining folding stateView Patent
6CA2474457Protein tag comprising a biotinylation domain and method for increasing solubility and determining folding stateView Patent
7EP1470229Protein tag comprising a biotinylation domain and method for increasing solubility and determining folding stateView Patent
8GB2361698 Modification of DNA moleculesView Patent
9EP1485411Arrays of cytosolic accessory proteins immobilized on a surface and pertinent methodsView Patent
10US8999897Protein tag comprising a biotinylation domain and method for increasing solubility and determining folding stateView Patent
11JP4730804Generating protein arraysView Patent
12JP4781628Protein arrays and their use for the allelic variantsView Patent
13US7816098Methods of making and using a protein arrayView Patent
14US20180305840Protein arrays and their use to assay the protein products of highly homologous or related DNA coding sequencesView Patent
NoPatent NumberDescriptionsView Patent
1US20180321244A1Method for detection and diagnosis of Oral Cancer in a sampleView Patent
2AU2018100578A4 Method for detection and diagnosis of Oral Cancer in a sampleView Patent
310201811119X Detection of biomarkers for Non-Small Cell Lung CancerView Patent
410201908922UIdentification of health status in the elderly using immunological biomarkersN/A
NoPatent NumberDescriptionsView Patent
110202011473YBiomarkers for predicting immunogenicity and therapeutic responses to adalimumab in rheumatoid arthritis patientsN/A

FEATURED PRODUCTS

High-throughput autoantibody profiling against 1600+ proteins

Quantification of autoantibodies to 200+ clinically relevant CT antigens

Simultaneous screening of 100+
wild-type and mutant p53

Multi-antigen, multi-domain
COVID-19 antibody test

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Copyright 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation LLC. Registered in Delaware, USA no. 5739583 | Sengenics UK Registered in England and Wales no. 12889389